Plasmodium vivax CSP-derived subunit vaccine formulations have been shown to be safe, well tolerated, and immunogenic in malaria-naïve volunteers, and have, therefore, enabled progression of this vaccine candidate to protective efficacy trials [4, 8]. This evidence concerns the gene DNAJC5 and malaria.